NCT04697628已完成3 期
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 502
- 试验地点
- 398
- 主要终点
- Overall Survival
研究概览
简要总结
This trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent).
Participants in this trial will be randomly assigned to one of two groups. One group will be treated with tisotumab vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which group they are in. Participants in the chemotherapy group will decide with their study doctor which drug they will take.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Has recurrent or metastatic cervical cancer with squamous cell, adenocarcinoma, or adenosquamous histology, and:
- •Has experienced disease progression during or after treatment with a standard of care systemic chemotherapy doublet, or platinum-based therapy (if eligible), defined as either:
- •paclitaxel + cisplatin + bevacizumab + anti-PD-(L)1 agent, or
- •paclitaxel + carboplatin + bevacizumab + anti-PD-(L)1 agent, or
- •paclitaxel + topotecan/nogitecan + bevacizumab + anti-PD-(L)1 agent
- •Note: In cases where bevacizumab and/or anti-PD-(L)1 agent is not a standard of care therapy or the participant was ineligible for such treatment according to local standards, prior treatment with bevacizumab and/or anti-PD-(L)1 agent is not required.
- •Has received 1 or 2 prior systemic therapy regimens for recurrent and/or metastatic cervical cancer. Chemotherapy administered in the adjuvant or neoadjuvant setting, or in combination with radiation therapy, should not be counted as a systemic therapy regimen. Single agent therapy with an anti-PD(L)1 agent for r/mCC cancer should be counted.
- •Measurable disease according to RECIST v1.1 as assessed by the investigator.
- •Has ECOG performance status of 0 or 1 prior to randomization.
- •Has life expectancy of at least 3 months.
排除标准
- •Has primary neuroendocrine, lymphoid, sarcomatoid, or other histologies not mentioned as part of the inclusion criteria above.
- •Has clinically significant bleeding issues or risks. This includes known past or current coagulation defects leading to an increased risk of bleeding; diffuse alveolar hemorrhage from vasculitis; known bleeding diathesis; ongoing major bleeding; trauma with increased risk of life-threatening bleeding or history of severe head trauma or intracranial surgery within 8 weeks of trial entry.
- •Has any history of intracerebral arteriovenous malformation, cerebral aneurysm, or stroke (transient ischemic attack >1 month prior to screening is allowed).
- •Active ocular surface disease or a history of cicatricial conjunctivitis or inflammatory conditions that predispose to cicatrizing conjunctivitis (e.g. Wagner syndrome, atopic keratoconjunctivitis, autoimmune disease affecting the eyes), ocular Stevens-Johnson syndrome or toxic epidermal necrolysis, mucus pemphigoid, and participants with penetrating ocular transplants. Cataracts alone is not an exclusion criterion.
- •Major surgery within 4 weeks or minor surgery within 7 days prior to the first study treatment administration.
- •Peripheral neuropathy ≥grade
- •Any prior treatment with monomethyl auristatin E (MMAE)-containing drugs.
- •There are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.
研究组 & 干预措施
Tisotumab vedotin
Experimental
Tisotumab vedotin monotherapy
干预措施: tisotumab vedotin (Drug)
Chemotherapy
Active Comparator
Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
干预措施: vinorelbine (Drug)
Chemotherapy
Active Comparator
Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
干预措施: gemcitabine (Drug)
Chemotherapy
Active Comparator
Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
干预措施: pemetrexed (Drug)
Chemotherapy
Active Comparator
Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
干预措施: irinotecan (Drug)
Chemotherapy
Active Comparator
Investigator's choice of one chemotherapy treatment (topotecan, vinorelbine, gemcitabine, irinotecan, or pemetrexed)
干预措施: topotecan (Drug)
结局指标
主要结局
Overall Survival
时间窗: From randomization to date of death due to any cause or censoring date, whichever occurred first (maximum up to 25 months)
Overall survival is defined as the time from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date the participant was known to be alive.
次要结局
- Progression Free Survival (PFS) as Assessed by Investigator(From the date of randomization to first documentation of PD or death due to any cause, or censoring date whichever occurred first (maximum up to 25 months))
- EQ-5D Visual Analog Scale (VAS) Scores(From start of treatment until end of follow-up)
- Confirmed Objective Response Rate (ORR) as Assessed by Investigator(From the date of randomization until date of confirmed CR or PR (maximum up to 25 months))
- Duration of Response (DOR) by Investigator Assessment(From the date of first documented response of CR or PR to the first documented PD or death from any cause, whichever occurred first (maximum up to 25 months))
- EuroQOL Five Dimensions Five Level (EQ-5D-5L) Index Score(From start of treatment until end of follow-up)
- European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Total Score(From start of treatment until end of follow-up)
- EORTC Quality of Life Questionnaire Cervical Cancer Module (QLQ-CX24) Total Scores(From start of treatment until end of follow-up)
- Time-to-Response (TTR) as Assessed by the Investigator(From the date of randomization to date of date of the first confirmed objective response (maximum up to 25 months))
- Number of Participants With Treatment Emergent Adverse Events (TEAEs)(From start of treatment up to 30 days after last dose of study treatment (up to 25 months))
研究者
研究点 (398)
Loading locations...
相似试验
已完成
2 期
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.Ovary CancerCervix CancerEndometrium CancerEsophagus CancerLung Cancer, Nonsmall CellSquamous Cell Carcinoma of the Head and NeckProstate CancerBladder CancerNCT03245736Seagen Inc.5
进行中（未招募）
3 期
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaStage IVA Laryngeal Squamous Cell Carcinoma AJCC v7Recurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Verrucous CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Verrucous CarcinomaRecurrent Salivary Gland CarcinomaStage IV Major Salivary Gland Cancer AJCC v7Stage IVA Laryngeal Verrucous Carcinoma AJCC v7Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7Neck Squamous Cell Carcinoma of Unknown PrimaryRecurrent Oropharyngeal Squamous Cell CarcinomaRecurrent Sinonasal Squamous Cell CarcinomaSalivary Gland Squamous Cell CarcinomaStage IVA Major Salivary Gland Cancer AJCC v7Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7Stage IVB Laryngeal Verrucous Carcinoma AJCC v7Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7Stage IVC Laryngeal Verrucous Carcinoma AJCC v7Recurrent Lip and Oral Cavity Squamous Cell CarcinomaStage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IVA Oral Cavity Cancer AJCC v6 and v7Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IVB Major Salivary Gland Cancer AJCC v7Stage IVC Oral Cavity Cancer AJCC v6 and v7Recurrent Neck Squamous Cell Carcinoma of Unknown PrimaryStage IVB Oral Cavity Cancer AJCC v6 and v7Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7Stage IVC Major Salivary Gland Cancer AJCC v7Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7Tongue CarcinomaNCT00588770National Cancer Institute (NCI)403
已完成
3 期
Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus CisplatinNon-small Cell Lung CancerNCT00966914BioNumerik Pharmaceuticals, Inc.540
进行中（未招募）
2 期
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid TumorsExocrine Pancreatic CancerCarcinoma, Non-Small-Cell LungCarcinoma, Squamous Cell of Head and NeckColorectal NeoplasmsNCT03485209Seagen, a wholly owned subsidiary of Pfizer350
已完成
3 期
Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)Pancreas AdenocarcinomaNCT03377491NovoCure Ltd.571
相关资讯
Zai Lab's Tivdak Shows Positive Results in China Subpopulation of Phase 3 Cervical Cancer Trial- Zai Lab's Tivdak demonstrated a 45% reduction in the risk of death compared to chemotherapy in Chinese patients with recurrent or metastatic cervical cancer.
- The China subpopulation results from the innovaTV 301 trial were consistent with global results, showing improved overall survival, PFS, and ORR.
- Zai Lab plans to submit a New Drug Application to China’s National Medical Products Administration in the first quarter of 2025.
- Tisotumab vedotin offers hope for addressing the unmet need for effective treatments after relapse, including after anti-PD(L)1 therapy.last yearTisotumab Vedotin Demonstrates Survival Benefit in Chinese Cervical Cancer Subpopulation- Tisotumab vedotin significantly improved overall survival compared to chemotherapy in Chinese patients with previously treated recurrent or metastatic cervical cancer.
- The antibody-drug conjugate reduced the risk of death by 45% in the Chinese subpopulation, consistent with global trial results.
- Zai Lab plans to submit a new drug application to China's National Medical Products Administration based on these findings.
- The results offer hope for addressing the unmet need for effective treatments after relapse, including after anti-PD-(L)1 therapy.last year